Related Experiment Video

Updated: May 16, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

TORCH study: how much longer should we continue to use erlotinib in unselected patients with non-small-cell lung

Vito Lorusso, Nicola Silvestris, Ilaria Marech

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |December 13, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques09:48

    Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques

    Published on: June 30, 2017

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...